poisar

Stocks · News reference

UBS Maintains Neutral Rating on Iovance Biotherapeutics and Raises Price Target to $8

UBS has updated its outlook on Iovance Biotherapeutics, Inc., maintaining a Neutral rating while increasing the price target from $7 to $8.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IOVA
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  4. Na

    IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress

    Iovance Biotherapeutics (IOVA) reported Q3 2026 revenues of $121.5M, surpassing estimates, with Amtagvi sales growing 77% to $102M. The company reaffirmed full-year revenue guidance of $410-$420M, highlighted improving gross margins at 60%, and advanced its pipeline with lung cancer and sarcoma trials targeting regulatory submissions in 2027-2029. Management expects cash resources to support operations into 2029.

    IOVA
  6. Earnings Transcripts

    Iovance Biotherapeutics Q3 2026 Earnings Call Transcript

    Iovance Biotherapeutics (NASDAQ:IOVA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by

    IOVA